Journal of Endocrinology

References

1. ↵
   1. Abdelhadi M,
   2. Ericzon BG,
   3. Hultenby K,
   4. Sjoden G,
   5. Reinholt FP &
   6. Nordenstrom J

   2002 Structural skeletal impairment induced by immunosuppressive therapy in rats: cyclosporine A vs tacrolimus. Transplant International 15 180–187.
2. ↵
   1. Adams JS &
   2. Hewison M

   2008 Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nature Clinical Practice. Endocrinology and Metabolism 4 80–90.
3. ↵
   1. Arlt W,
   2. Hammer F,
   3. Sanning P,
   4. Butcher SK,
   5. Lord JM,
   6. Allolio B,
   7. Annane D &
   8. Stewart PM

   2006 Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. Journal of Clinical Endocrinology and Metabolism 91 2548–2554.
4. ↵
   1. Armstrong VJ,
   2. Muzylak M,
   3. Sunters A,
   4. Zaman G,
   5. Saxon LK,
   6. Price JS &
   7. Lanyon LE

   2007 Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. Journal of Biological Chemistry 282 20715–20727.
5. ↵
   1. Beishuizen A,
   2. Thijs LG &
   3. Vermes I

   2002 Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve? Critical Care 6 434–438.
6. ↵
   1. Bejsovec A

   2000 Wnt signaling: an embarrassment of receptors. Current Biology 10 R919–R922.
7. ↵
   1. Bellows CG,
   2. Heersche JN &
   3. Aubin JE

   1990 Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone. Developmental Biology 140 132–138.
8. ↵
   1. Bernstein CN,
   2. Blanchard JF,
   3. Leslie W,
   4. Wajda A &
   5. Yu BN

   2000 The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Annals of Internal Medicine 133 795–799.
9. ↵
   1. Bonewald LF &
   2. Johnson ML

   2008 Osteocytes, mechanosensing and Wnt signaling. Bone 42 606–615.
10. ↵
    1. Boyden LM,
    2. Mao J,
    3. Belsky J,
    4. Mitzner L,
    5. Farhi A,
    6. Mitnick MA,
    7. Wu D,
    8. Insogna K &
    9. Lifton RP

    2002 High bone density due to a mutation in LDL-receptor-related protein 5. New England Journal of Medicine 346 1513–1521.
11. ↵
    1. Bryndova J,
    2. Zbankova S,
    3. Kment M &
    4. Pacha J

    2004 Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scandinavian Journal of Gasteroenterology 39 549–553.
12. ↵
    1. Bultink IE,
    2. Lems WF,
    3. Kostense PJ,
    4. Dijkmans BA &
    5. Voskuyl AE

    2005 Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis and Rheumatism 52 2044–2050.
13. ↵
    1. Burnham JM,
    2. Shults J,
    3. Petit MA,
    4. Semeao E,
    5. Beck TJ,
    6. Zemel BS &
    7. Leonard MB

    2007 Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: impact of the underlying disease. Journal of Bone and Mineral Research 22 551–559.
14. ↵
    1. Canalis E &
    2. Delany AM

    2002 11β-hydroxysteroid dehydrogenase, an amplifier of glucocorticoid action in osteoblasts. Journal of Bone and Mineral Research 17 987–990.
15. ↵
    1. Canalis E,
    2. Mazziotti G,
    3. Giustina A &
    4. Bilezikian JP

    2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International 18 1319–1328.
16. ↵
    1. Carmeliet G &
    2. Bouillon R

    1999 The effect of microgravity on morphology and gene expression of osteoblasts in vitro. FASEB Journal 13 S129–S134.
17. ↵
    1. Chiodini I,
    2. Carnevale V,
    3. Torlontano M,
    4. Fusilli S,
    5. Guglielmi G,
    6. Pileri M,
    7. Modoni S,
    8. Di Giorgio A,
    9. Liuzzi A,
    10. Minisola S
    11. et al.

    1998 Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 83 1863–1867.
18. ↵
    1. Cohen SB,
    2. Dore RK,
    3. Lane NE,
    4. Ory PA,
    5. Peterfy CG,
    6. Sharp JT,
    7. van der HD,
    8. Zhou L,
    9. Tsuji W &
    10. Newmark R

    2008 Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis and Rheumatism 58 1299–1309.
19. ↵
    1. Cooper MS

    2004 Sensitivity of bone to glucocorticoids. Clinical Science 107 111–123.
20. ↵
    1. Cooper MS &
    2. Gittoes NJ

    2008 Diagnosis and management of hypocalcaemia. BMJ 336 1298–1302.
21. ↵
    1. Cooper MS,
    2. Walker EA,
    3. Bland R,
    4. Fraser WD,
    5. Hewison M &
    6. Stewart PM

    2000 Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 27 375–381.
22. ↵
    1. Cooper MS,
    2. Bujalska I,
    3. Rabbitt E,
    4. Walker EA,
    5. Bland R,
    6. Sheppard MC,
    7. Hewison M &
    8. Stewart PM

    2001 Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Journal of Bone and Mineral Research 16 1037–1044.
23. ↵
    1. Cooper MS,
    2. Blumsohn A,
    3. Goddard PE,
    4. Bartlett WA,
    5. Shackleton CH,
    6. Eastell R,
    7. Hewison M &
    8. Stewart PM

    2003 11β-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. Journal of Clinical Endocrinology and Metabolism 88 3874–3877.
24. ↵
    1. Corazza GR,
    2. Di SM,
    3. Maurino E &
    4. Bai JC

    2005 Bones in coeliac disease: diagnosis and treatment. Best Practice & Research. Clinical Gastroenterology 19 453–465.
25. ↵
    1. Diarra D,
    2. Stolina M,
    3. Polzer K,
    4. Zwerina J,
    5. Ominsky MS,
    6. Dwyer D,
    7. Korb A,
    8. Smolen J,
    9. Hoffmann M,
    10. Scheinecker C
    11. et al.

    2007 Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine 13 156–163.
26. ↵
    1. Dougall WC,
    2. Glaccum M,
    3. Charrier K,
    4. Rohrbach K,
    5. Brasel K,
    6. De ST,
    7. Daro E,
    8. Smith J,
    9. Tometsko ME,
    10. Maliszewski CR
    11. et al.

    1999 RANK is essential for osteoclast and lymph node development. Genes and Development 13 2412–2424.
27. ↵
    1. Eastell R

    2005 Role of oestrogen in the regulation of bone turnover at the menarche. Journal of Endocrinology 185 223–234.
28. ↵
    1. Eijken M,
    2. Koedam M,
    3. van Driel M,
    4. Buurman CJ,
    5. Pols HA &
    6. van Leeuwen JP

    2006 The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Molecular and Cellular Endocrinology 248 87–93.
29. ↵
    Fernandez-Rodriguez E, Stewart PM & Cooper MS 2008 The pituitary–adrenal axis and body composition. Pituitary (in press).
30. ↵
    1. Froicu M &
    2. Cantorna MT

    2007 Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunology 8 5.
31. ↵
    1. Gilbert L,
    2. He X,
    3. Farmer P,
    4. Boden S,
    5. Kozlowski M,
    6. Rubin J &
    7. Nanes MS

    2000 Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 141 3956–3964.
32. ↵
    1. Goldring SR &
    2. Goldring MB

    2007 Eating bone or adding it: the Wnt pathway decides. Nature Medicine 13 133–134.
33. ↵
    1. Gong Y,
    2. Slee RB,
    3. Fukai N,
    4. Rawadi G,
    5. Roman-Roman S,
    6. Reginato AM,
    7. Wang H,
    8. Cundy T,
    9. Glorieux FH,
    10. Lev D
    11. et al.

    2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 513–523.
34. ↵
    1. Gough AK,
    2. Lilley J,
    3. Eyre S,
    4. Holder RL &
    5. Emery P

    1994 Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344 23–27.
35. ↵
    1. Gravallese EM,
    2. Manning C,
    3. Tsay A,
    4. Naito A,
    5. Pan C,
    6. Amento E &
    7. Goldring SR

    2000 Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and Rheumatism 43 250–258.
36. ↵
    1. Hansen M,
    2. Florescu A,
    3. Stoltenberg M,
    4. Podenphant J,
    5. Pedersen-Zbinden B,
    6. Horslev-Petersen K,
    7. Hyldstrup L &
    8. Lorenzen I

    1996 Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scandinavian Journal of Rheumatology 25 367–376.
37. ↵
    1. Hardy RS,
    2. Filer A,
    3. Cooper MS,
    4. Parsonage G,
    5. Raza K,
    6. Hardie DL,
    7. Rabbitt EH,
    8. Stewart PM,
    9. Buckley CD &
    10. Hewison M

    2006 Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Research and Therapy 8 R108.
38. ↵
    1. Hardy R,
    2. Rabbitt EH,
    3. Filer A,
    4. Emery P,
    5. Hewison M,
    6. Stewart PM,
    7. Gittoes NJ,
    8. Buckley CD,
    9. Raza K &
    10. Cooper MS

    2008 Local and systemic glucocorticoid metabolism in inflammatory arthritis. Annals of the Rheumatic Diseases 67 1204–1210.
39. ↵
    1. Herman S,
    2. Kronke G &
    3. Schett G

    2008 Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends in Molecular Medicine 14 245–253.
40. ↵
    1. Hewison M,
    2. Freeman L,
    3. Hughes SV,
    4. Evans KN,
    5. Bland R,
    6. Eliopoulos AG,
    7. Kilby MD,
    8. Moss PA &
    9. Chakraverty R

    2003 Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. Journal of Immunology 170 5382–5390.
41. ↵
    1. Hofbauer LC,
    2. Gori F,
    3. Riggs BL,
    4. Lacey DL,
    5. Dunstan CR,
    6. Spelsberg TC &
    7. Khosla S

    1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 4382–4389.
42. ↵
    1. Hofbauer LC,
    2. Khosla S,
    3. Dunstan CR,
    4. Lacey DL,
    5. Boyle WJ &
    6. Riggs BL

    2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 15 2–12.
43. ↵
    1. Hu H,
    2. Hilton MJ,
    3. Tu X,
    4. Yu K,
    5. Ornitz DM &
    6. Long F

    2005 Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132 49–60.
44. ↵
    1. Jilka RL,
    2. Weinstein RS,
    3. Bellido T,
    4. Roberson P,
    5. Parfitt AM &
    6. Manolagas SC

    1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation 104 439–446.
45. ↵
    1. Johnson ML,
    2. Harnish K,
    3. Nusse R &
    4. Van HW

    2004 LRP5 and Wnt signaling: a union made for bone. Journal of Bone and Mineral Research 19 1749–1757.
46. ↵
    1. Karsenty G

    2006 Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metabolism 4 341–348.
47. ↵
    1. Kim N,
    2. Kadono Y,
    3. Takami M,
    4. Lee J,
    5. Lee SH,
    6. Okada F,
    7. Kim JH,
    8. Kobayashi T,
    9. Odgren PR,
    10. Nakano H
    11. et al.

    2005 Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. Journal of Experimental Medicine 202 589–595.
48. ↵
    1. Kirwan JR

    1995 The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. New England Journal of Medicine 333 142–146.
49. ↵
    1. Kobayashi K,
    2. Takahashi N,
    3. Jimi E,
    4. Udagawa N,
    5. Takami M,
    6. Kotake S,
    7. Nakagawa N,
    8. Kinosaki M,
    9. Yamaguchi K,
    10. Shima N
    11. et al.

    2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL–RANK interaction. Journal of Experimental Medicine 191 275–286.
50. ↵
    1. Kong YY,
    2. Feige U,
    3. Sarosi I,
    4. Bolon B,
    5. Tafuri A,
    6. Morony S,
    7. Capparelli C,
    8. Li J,
    9. Elliott R,
    10. McCabe S
    11. et al.

    1999a Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 304–309.
51. ↵
    1. Kong YY,
    2. Yoshida H,
    3. Sarosi I,
    4. Tan HL,
    5. Timms E,
    6. Capparelli C,
    7. Morony S,
    8. Oliveira-dos-Santos AJ,
    9. Van G,
    10. Itie A
    11. et al.

    1999b OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 315–323.
52. ↵
    1. Kotake S,
    2. Udagawa N,
    3. Hakoda M,
    4. Mogi M,
    5. Yano K,
    6. Tsuda E,
    7. Takahashi K,
    8. Furuya T,
    9. Ishiyama S,
    10. Kim KJ
    11. et al.

    2001 Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis and Rheumatism 44 1003–1012.
53. ↵
    1. Leonard MB,
    2. Feldman HI,
    3. Shults J,
    4. Zemel BS,
    5. Foster BJ &
    6. Stallings VA

    2004 Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. New England Journal of Medicine 351 868–875.
54. ↵
    1. Li J,
    2. Sarosi I,
    3. Yan XQ,
    4. Morony S,
    5. Capparelli C,
    6. Tan HL,
    7. McCabe S,
    8. Elliott R,
    9. Scully S,
    10. Van G
    11. et al.

    2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. PNAS 97 1566–1571.
55. ↵
    1. Lien G,
    2. Flato B,
    3. Haugen M,
    4. Vinje O,
    5. Sorskaar D,
    6. Dale K,
    7. Johnston V,
    8. Egeland T &
    9. Forre O

    2003 Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis and Rheumatism 48 2214–2223.
56. ↵
    1. Little RD,
    2. Carulli JP,
    3. Del Mastro RG,
    4. Dupuis J,
    5. Osborne M,
    6. Folz C,
    7. Manning SP,
    8. Swain PM,
    9. Zhao SC,
    10. Eustace B
    11. et al.

    2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. American Journal of Human Genetics 70 11–19.
57. ↵
    1. Liu PT,
    2. Stenger S,
    3. Li H,
    4. Wenzel L,
    5. Tan BH,
    6. Krutzik SR,
    7. Ochoa MT,
    8. Schauber J,
    9. Wu K,
    10. Meinken C
    11. et al.

    2006 Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 1770–1773.
58. ↵
    1. Lorenzo J,
    2. Horowitz M &
    3. Choi Y

    2008 Osteoimmunology: interactions of the bone and immune system. Endocrine Reviews 29 403–440.
59. ↵
    1. Lundy SK,
    2. Sarkar S,
    3. Tesmer LA &
    4. Fox DA

    2007 Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research and Therapy 9 202.
60. ↵
    1. Manolagas SC &
    2. Jilka RL

    1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. New England Journal of Medicine 332 305–311.
61. ↵
    1. Manolagas SC &
    2. Weinstein RS

    1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. Journal of Bone and Mineral Research 14 1061–1066.
62. ↵
    1. Matsuo K &
    2. Irie N

    2008 Osteoclast–osteoblast communication. Archives of Biochemistry and Biophysics 473 201–209.
63. ↵
    1. Merlino LA,
    2. Curtis J,
    3. Mikuls TR,
    4. Cerhan JR,
    5. Criswell LA &
    6. Saag KG

    2004 Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis and Rheumatism 50 72–77.
64. ↵
    1. Miller KK,
    2. Lee EE,
    3. Lawson EA,
    4. Misra M,
    5. Minihan J,
    6. Grinspoon SK,
    7. Gleysteen S,
    8. Mickley D,
    9. Herzog D &
    10. Klibanski A

    2006 Determinants of skeletal loss and recovery in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 91 2931–2937.
65. ↵
    1. Minaur NJ,
    2. Kounali D,
    3. Vedi S,
    4. Compston JE,
    5. Beresford JN &
    6. Bhalla AK

    2002 Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 41 741–749.
66. ↵
    1. Monegal A,
    2. Navasa M,
    3. Guanabens N,
    4. Peris P,
    5. Pons F,
    6. Martinez de Osaba MJ,
    7. Rimola A,
    8. Rodes J &
    9. Munoz-Gomez J

    2001 Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcified Tissue International 68 83–86.
67. ↵
    1. Morvan F,
    2. Boulukos K,
    3. Clement-Lacroix P,
    4. Roman RS,
    5. Suc-Royer I,
    6. Vayssiere B,
    7. Ammann P,
    8. Martin P,
    9. Pinho S,
    10. Pognonec P
    11. et al.

    2006 Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. Journal of Bone and Mineral Research 21 934–945.
68. ↵
    1. Nair KS,
    2. Rizza RA,
    3. O'Brien P,
    4. Dhatariya K,
    5. Short KR,
    6. Nehra A,
    7. Vittone JL,
    8. Klee GG,
    9. Basu A,
    10. Basu R
    11. et al.

    2006 DHEA in elderly women and DHEA or testosterone in elderly men. New England Journal of Medicine 355 1647–1659.
69. ↵
    1. Nakashima T,
    2. Kobayashi Y,
    3. Yamasaki S,
    4. Kawakami A,
    5. Eguchi K,
    6. Sasaki H &
    7. Sakai H

    2000 Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochemical and Biophysical Research Communications 275 768–775.
70. ↵
    1. Pearce G,
    2. Tabensky DA,
    3. Delmas PD,
    4. Baker HW &
    5. Seeman E

    1998 Corticosteroid-induced bone loss in men. Journal of Clinical Endocrinology and Metabolism 83 801–806.
71. ↵
    1. Pers JO,
    2. Saraux A,
    3. Pierre R &
    4. Youinou P

    2008 Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. Journal of Periodontology 79 1645–1651.
72. ↵
    1. Poole KE &
    2. Reeve J

    2005 Parathyroid hormone – a bone anabolic and catabolic agent. Current Opinion in Pharmacology 5 612–617.
73. ↵
    1. Rabbitt E,
    2. Lavery GG,
    3. Walker EA,
    4. Cooper MS,
    5. Stewart PM &
    6. Hewison M

    2002 Pre-receptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB Journal 16 36–44.
74. ↵
    1. Rall LC &
    2. Roubenoff R

    2004 Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 43 1219–1223.
75. ↵
    1. Russell RG,
    2. Watts NB,
    3. Ebetino FH &
    4. Rogers MJ

    2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 19 733–759.
76. ↵
    1. Saag KG,
    2. Shane E,
    3. Boonen S,
    4. Marin F,
    5. Donley DW,
    6. Taylor KA,
    7. Dalsky GP &
    8. Marcus R

    2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis. New England Journal of Medicine 357 2028–2039.
77. ↵
    1. Sambrook PN

    2000 Corticosteroid osteoporosis: practical implications of recent trials. Journal of Bone and Mineral Research 15 1645–1649.
78. ↵
    1. Sambrook PN

    2007 Anabolic therapy in glucocorticoid-induced osteoporosis. New England Journal of Medicine 357 2084–2086.
79. ↵
    1. Sato K,
    2. Suematsu A,
    3. Okamoto K,
    4. Yamaguchi A,
    5. Morishita Y,
    6. Kadono Y,
    7. Tanaka S,
    8. Kodama T,
    9. Akira S,
    10. Iwakura Y
    11. et al.

    2006 Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. Journal of Experimental Medicine 203 2673–2682.
80. ↵
    1. Schett G,
    2. Kiechl S,
    3. Weger S,
    4. Pederiva A,
    5. Mayr A,
    6. Petrangeli M,
    7. Oberhollenzer F,
    8. Lorenzini R,
    9. Redlich K,
    10. Axmann R
    11. et al.

    2006 High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Archives of Internal Medicine 166 2495–2501.
81. ↵
    1. Schoon EJ,
    2. Blok BM,
    3. Geerling BJ,
    4. Russel MG,
    5. Stockbrugger RW &
    6. Brummer RJ

    2000 Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 119 1203–1208.
82. ↵
    1. Simonet WS,
    2. Lacey DL,
    3. Dunstan CR,
    4. Kelley M,
    5. Chang MS,
    6. Luthy R,
    7. Nguyen HQ,
    8. Wooden S,
    9. Bennett L,
    10. Boone T
    11. et al.

    1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 309–319.
83. ↵
    1. Sims NA &
    2. Gooi JH

    2008 Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Seminars in Cell and Developmental Biology 19 444–451.
84. ↵
    1. Soyka LA,
    2. Grinspoon S,
    3. Levitsky LL,
    4. Herzog DB &
    5. Klibanski A

    1999 The effects of anorexia nervosa on bone metabolism in female adolescents. Journal of Clinical Endocrinology and Metabolism 84 4489–4496.
85. ↵
    1. Spector TD,
    2. Hall GM,
    3. McCloskey EV &
    4. Kanis JA

    1993 Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 306 558.
86. ↵
    Stegk JP, Ebert B, Martin HJ & Maser E 2009 Expression profiles of human 11β-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Molecular and Cellular Endocrinology 301 104–108..
87. ↵
    1. Sylvester FA,
    2. Wyzga N,
    3. Hyams JS,
    4. Davis PM,
    5. Lerer T,
    6. Vance K,
    7. Hawker G &
    8. Griffiths AM

    2007 Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflammatory Bowel Diseases 13 42–50.
88. ↵
    1. Tesmer LA,
    2. Lundy SK,
    3. Sarkar S &
    4. Fox DA

    2008 Th17 cells in human disease. Immunological Reviews 223 87–113.
89. ↵
    1. Thomson BM,
    2. Mundy GR &
    3. Chambers TJ

    1987 Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. Journal of Immunology 138 775–779.
90. ↵
    1. Tian E,
    2. Zhan F,
    3. Walker R,
    4. Rasmussen E,
    5. Ma Y,
    6. Barlogie B &
    7. Shaughnessy JD Jr.

    2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine 349 2483–2494.
91. ↵
    1. Tobias JH,
    2. Sasi MR,
    3. Greenwood R &
    4. Probert CS

    2004 Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. Alimentary Pharmacology and Therapeutics 20 951–957.
92. ↵
    1. Tomlinson JW,
    2. Moore J,
    3. Cooper MS,
    4. Bujalska I,
    5. Shahmanesh M,
    6. Burt C,
    7. Strain A,
    8. Hewison M &
    9. Stewart PM

    2001 Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142 1982–1989.
93. ↵
    1. Tomlinson JW,
    2. Walker EA,
    3. Bujalska IJ,
    4. Draper N,
    5. Lavery GG,
    6. Cooper MS,
    7. Hewison M &
    8. Stewart PM

    2004 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews 25 831–866.
94. ↵
    1. Vis M,
    2. Havaardsholm EA,
    3. Haugeberg G,
    4. Uhlig T,
    5. Voskuyl AE,
    6. van de Stadt RJ,
    7. Dijkmans BA,
    8. Woolf AD,
    9. Kvien TK &
    10. Lems WF

    2006 Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 65 1495–1499.
95. ↵
    1. Wang FS,
    2. Ko JY,
    3. Yeh DW,
    4. Ke HC &
    5. Wu HL

    2008 Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149 1793–1801.
96. ↵
    1. Weinstein RS,
    2. Jilka RL,
    3. Parfitt AM &
    4. Manolagas SC

    1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. Journal of Clinical Investigation 102 274–282.
97. ↵
    1. Weinstein RS,
    2. Chen JR,
    3. Powers CC,
    4. Stewart SA,
    5. Landes RD,
    6. Bellido T,
    7. Jilka RL,
    8. Parfitt AM &
    9. Manolagas SC

    2002 Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. Journal of Clinical Investigation 109 1041–1048.
98. ↵
    1. Weinstein RS,
    2. Jia D,
    3. Powers CC,
    4. Stewart SA,
    5. Jilka RL,
    6. Parfitt AM &
    7. Manolagas SC

    2004 The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145 1980–1987.
99. ↵
    1. Westendorf JJ,
    2. Kahler RA &
    3. Schroeder TM

    2004 Wnt signaling in osteoblasts and bone diseases. Gene 341 19–39.
100. ↵
     Wetzsteon RJ, Shults J, Zemel BS, Gupta PU, Burnham JM, Herskovitz RM, Howard KM & Leonard MB 2009 Divergent effects of glucocorticoids on cortical and trabecular compartment bone mineral density in childhood nephrotic syndrome. Journal of Bone and Mineral Research 24 503–513..
101. ↵
     1. Wodarz A &
     2. Nusse R

     1998 Mechanisms of Wnt signaling in development. Annual Review of Cell and Development Biology 14 59–88.
102. ↵
     1. Zehnder D,
     2. Quinkler M,
     3. Eardley KS,
     4. Bland R,
     5. Lepenies J,
     6. Hughes SV,
     7. Raymond NT,
     8. Howie AJ,
     9. Cockwell P,
     10. Stewart PM
     11. et al.

     2008 Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney International 74 1343–1353.
103. ↵
     1. Zhao C,
     2. Irie N,
     3. Takada Y,
     4. Shimoda K,
     5. Miyamoto T,
     6. Nishiwaki T,
     7. Suda T &
     8. Matsuo K

     2006 Bidirectional ephrinB2–EphB4 signaling controls bone homeostasis. Cell Metabolism 4 111–121.